Contemporary advances in anti-NMDAR antibody (Ab)-mediated encephalitis.
Seery N, Butzkueven H, O'Brien TJ, Monif M.
Autoimmun Rev. 2022 Apr;21(4):103057. doi: 10.1016/j.autrev.2022.103057. Epub 2022 Jan 31.
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R.
Lancet Neurol. 2011 Jan;10(1):63-74. doi: 10.1016/S1474-4422(10)70253-2.
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J.
Lancet Neurol. 2013 Feb;12(2):157-65. doi: 10.1016/S1474-4422(12)70310-1. Epub 2013 Jan 3.
Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms.
Lynch DR, Rattelle A, Dong YN, Roslin K, Gleichman AJ, Panzer JA.
Adv Pharmacol. 2018;82:235-260. doi: 10.1016/bs.apha.2017.08.005. Epub 2017 Nov 8.
State of the Art: Acute Encephalitis.
Bloch KC, Glaser C, Gaston D, Venkatesan A.
Clin Infect Dis. 2023 Sep 11;77(5):e14-e33. doi: 10.1093/cid/ciad306.
Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy.
Bastiaansen AEM, de Bruijn MAAM, Schuller SL, Martinez-Hernandez E, Brenner J, Paunovic M, Crijnen YS, Mulder MJHL, Schreurs MWJ, de Graaff E, Smitt PAE, Neuteboom RF, de Vries JM, Titulaer MJ.
Neurol Neuroimmunol Neuroinflamm. 2021 Dec 22;9(2):e1127. doi: 10.1212/NXI.0000000000001127. Print 2022 Mar.
Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.
Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, Kreye J, Sánchez-Sendín E, Blumenau S, Stappert D, Radbruch H, Hauser AE, Künkele A, Edes I, Schmitz D, Prüss H.
Cell. 2023 Nov 9;186(23):5084-5097.e18. doi: 10.1016/j.cell.2023.10.001. Epub 2023 Nov 1.
Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.
Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M; International NMDAR Antibody Encephalitis Consensus Group; Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK.
JAMA Neurol. 2021 Nov 1;78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188.
Transfer of patient's peripheral blood mononuclear cells (PBMCs) disrupts blood-brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model.
Shu Y, Peng F, Zhao B, Liu C, Li Q, Li H, Wang Y, Jiang Y, Lu T, Wang Q, Sun J, Feng H, Lu Z, Liu X, Wang J, Qiu W.
J Neuroinflammation. 2023 Jul 13;20(1):164. doi: 10.1186/s12974-023-02844-4.
Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children.
Hou C, Wu W, Tian Y, Zhang Y, Zhu H, Zeng Y, Peng B, Zheng K, Li X, Chen W.
Mult Scler Relat Disord. 2020 Jul;42:102018. doi: 10.1016/j.msard.2020.102018. Epub 2020 Feb 22.
